Track topics on Twitter Track topics that are important to you
We hypothesize the addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, and enable a more rapid and effective steroid taper.
Effective treatments for chronic GVHD are currently limited to corticosteroids, and often requires prolonged treatment. The addition of a calcineurin inhibitor is not associated with an increased response rate or transplant-related mortality. Our laboratory studies have demonstrated allogeneic antibodies develop in association with chronic GVHD after HSCT. This implicates allogeneic B cell responses in the pathogenesis of chronic GVHD and supports testing anti-B cell therapy for chronic GVHD. In our DFCI phase I trial of 21 patients with steroid refractory chronic GVHD, rituximab provided 70% overall responses and 2 complete responses. Rituximab therapy facilitated corticosteroid tapering with a median dose of prednisone falling from 40 mg/day at trial initiation to 10 mg/day at one year (p = 0.0002). We hypothesize the addition of rituximab to prednisone for the initial treatment of chronic GVHD will increase the overall response rate, and enable a more rapid and effective steroid taper. If B cells or their product antibodies are contributing to chronic GVHD pathogenesis, and prednisone efficacy is partially active through a less-specific B cell effect, then it follows that rituximab addition to prednisone may increase chronic GVHD response rates and enable successful steroid tapering. To test this hypothesis, we have initiated a phase II clinical trial of rituximab and corticosteroids as front line therapy for patients with newly diagnosed chronic GVHD. Reported cGVHD trials have tested the benefit of adding an experimental agent to prednisone dosed 1mg/kg for 4 or 9 months before slowly tapering again on a fixed schedule. In these trials the primary endpoint was the cGVHD complete response rate, and 1mg/kg every other day prednisone yielded a 33% CR and 62% overall response rate after 9 months therapy thereby setting a standard for what single agent high-dose prednisone can achieve alone. However, long-term single-agent high-dose corticosteroid treatment of cGVHD causes significant morbidity being associated 20% incidence avascular necrosis. On that trial, only 50% could be weaned from steroids at 5 years. With this steroid toxicity in mind, we believe a clinically meaningful endpoint for phase II testing of promising cGVHD drugs may be their addition to high-dose steroids enables a successful steroid taper. As such, our primary endpoint is the ability to successfully taper prednisone to a dose of 0.25 mg/kg/day or less by six months without cGVHD relapse. The 0.25mg/kg/day primary endpoint was chosen for both physiological and clinical practice reasons. Patients receiving prednisone 20mg daily or greater are assumed to have functional suppression of hypothalamic-pituitary-adrenal function, frequently suffer steroid toxicities. Clinically, many HSCT clinicians taper patients to 10-20 mg prednisone a day and then only slowly further taper to avoid chronic GVHD recurrence.
Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Graft vs Host Disease
Stanford University School of Medicine
Published on BioPortfolio: 2014-08-27T03:43:35-0400
The purpose of this study is to determine whether low-doses alemtuzumab and rituximab combination are effective in the treatment of chronic graft-versus-host disease (GVHD) after first-lin...
The main objective of the study is to improve the response rate (complete and partial remission) at 12 months after diagnosis of chronic Chronic Graft Versus Host Disease (GVHD) and treatm...
The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).
Rituximab is an attractive agent to bring to the upfront treatment of cGVHD due to its favorable toxicity profile, its proven efficacy in the treatment of steroid-refractory chronic GVHD, ...
This pilot phase II trial studies how well carfilzomib works in treating patients with chronic graft-versus-host disease. Chronic graft-versus-host disease is a complication of a donor bon...
Sclerodermatous graft-versus-host disease is a subtype of cutaneous chronic graft-versus-host disease that is characterized by sclerosis of the skin and subcutaneous tissue, resulting in debilitating ...
Upper gastrointestinal acute graft-versus-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-versus-host disease. Currently classifie...
This study reports the incidence, anatomic location, and outcomes of graft-versus-host disease (GVHD) at a single active intestine transplant center.
Graft-versus-host disease (GVHD) is a severe adverse effect that results from bone marrow or peripheral blood cells transplantation and has a high rate of mortality. About 50% of the patients are acco...
Bone Marrow Transplant (BMT) is a lifesaving procedure for a range of serious benign or malignant hematological conditions. A proportion of patients however will develop Graft Versus Host Disease (GVH...
An immunological attack mounted by a graft against the host because of tissue incompatibility when immunologically competent cells are transplanted to an immunologically incompetent host; the resulting clinical picture is that of GRAFT VS HOST DISEASE.
The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
The immune responses of a host to a graft. A specific response is GRAFT REJECTION.
The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...